Updates in the Treatment of HR+ Breast Cancer : Episode 4
Opinion
Video
Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.
Video content above is prompted by the following:
- For a patient whose cancer has progressed, do you obtain a new biopsy or go back to the original sample? Why?
- What biomarkers do you test for in advanced-stage breast cancer and when? Is there a need for NGS testing before first-line metastatic disease? (eg, BRCA, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, TMB-H)
Related Videos
Related Content
